PCSK9: Could their plasma levels and CD34+CPCS predict PWV improvement in optimized lipid lowering strategy?

Background and Aims: In the era of innovative therapies, non-statin lipid lowering treatments are gaining increasing attention. Research currently also focuses on the identification of novel biomarkers in atherosclerosis, with pulse wave velocity (PWV), circulating CD34+ progenitor cells (CD34+CPCs) and PCSK9 plasma levels looking like promising markers. Our study aimed to evaluate the effects of LDL-C lowering on PWV, the correlation of PCSK9 plasma levels and CD34+CPCs with PWV, and their changes with PCSK9 inhibitors (PCSK9-i).